NLRP3 inflammasome inhibitor and application thereof

An inflammasome and inhibitor technology, applied in the field of life sciences, can solve problems such as lack of effective drug treatment methods

Pending Publication Date: 2020-06-26
THE SECOND HOSPITAL AFFILIATED TO WENZHOU MEDICAL COLLEGE
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

About 3 million patients worldwide suffer from ALI / ARDS each year, accounting for 10% of the total number of patients in intensive care units; despite the deepening understanding of its pathophysiological mechanism, there is still a lack of effective drug treatment, and the mortality rate of ALI / ARDS remains high. up to 35%-46%, therefore, it is imminent to find new effective treatment drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • NLRP3 inflammasome inhibitor and application thereof
  • NLRP3 inflammasome inhibitor and application thereof
  • NLRP3 inflammasome inhibitor and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0023] In order to make the object, technical solution and advantages of the present invention clearer, the present invention will be described in further detail below in conjunction with specific implementation methods and with reference to the accompanying drawings.

[0024] Experiment grouping and processing

[0025] The first part of the experiment: Wild-type male C57BL / 6 mice (22-25g) were randomly divided into 4 groups, 24 in each group. ①Control group: intraperitoneal injection of equal volume of 0.9% sodium chloride injection; ②LPS group: intraperitoneal injection of lipopolysaccharide (LPS) 15 mg / kg; ③LPS+erythropoietin treatment group (LPS+EPO group): intraperitoneal injection of lipopolysaccharide (LPS) 15 mg / kg, and intraperitoneal injection of erythropoietin (EPO) 3000 U / kg; ④ Erythropoietin group (EPO group): intraperitoneal injection of erythropoietin (EPO) ) 3000U / kg. Eight hours later, mice were anesthetized by intraperitoneal injection of 1% pentobarbital...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an NLRP3 inflammasome inhibitor which is EPO (erythropoietin), and provides application of the NLRP3 inflammasome inhibitor in preparing a medicine for treating diseases with uncontrolled inflammation reactions as characteristics. According to the NLRP3 inflammasome inhibitor disclosed by the invention, LPS induced ALI (acute lung injury) mouse NLRP3 inflammasome is inhibited by using an EPOR / JAK2 / STAT3 / NF-kB signal channel, a completely new mechanism that LPS induced acute lung injury is reduced by EPO is revealed, and novel strategies and treatment targets are provided for treatment on diseases such as ALI / ARDS (acute respiratory distress syndrome) with uncontrolled inflammation reactions as characteristics.

Description

technical field [0001] The invention belongs to the field of life sciences, and in particular relates to an inhibitor of NLRP3 inflammasome and the use of the NLRP3 inflammasome inhibitor in the preparation of medicines for treating diseases characterized by uncontrolled inflammatory responses. Background technique [0002] Acute lung injury (ALI) / acute respiratory distress syndrome (ARDS) is non-cardiogenic acute hypoxic respiratory failure caused by various intrapulmonary and extrapulmonary factors. Progressive dyspnea and refractory hypoxemia. About 3 million patients worldwide suffer from ALI / ARDS every year, accounting for 10% of the total number of patients in intensive care units; despite the deepening understanding of its pathophysiological mechanism, there is still a lack of effective drug treatment, and the mortality rate of ALI / ARDS remains high. As high as 35%-46%, therefore, it is imminent to find new effective treatment drugs. [0003] The uncontrolled inflam...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/18A61P29/00A61P11/00
CPCA61K38/1816A61P29/00A61P11/00
Inventor 高叶金胜威曹飞田心毅
Owner THE SECOND HOSPITAL AFFILIATED TO WENZHOU MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap